InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,469.07
(
-0.25%
)
US TECH 100
19,224.80
(
-0.21%
)
Dow Jones
39,042.68
(
-0.31%
)
Brent Oil
84.80
(
-0.73%
)
Bitcoin
60,288.56
(
-2.15%
)
Post# of 252422
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

FreeNorth

Send PM Follow Ignore
Followers 1
Posts 81
Boards Moderated 0
Alias Born 07/27/2006

FreeNorth

Member Level

Re: north40000 post# 193971

Thursday, 08/06/2015 7:04:46 PM

Thursday, August 06, 2015 7:04:46 PM

Post# of 252422
It wasn't a direct route from Canada to Merck

AMES, Iowa, July 31, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NLNK) today announced that the international partnership studying the VSV-ZEBOV (Ebola) vaccine candidate in Guinea has released interim data suggesting that it is effective against Ebola in a large clinical trial. According to the announcement, the interim results suggest that the vaccine candidate demonstrates efficacy within about 10 days of administration to a person without the infection.

The VSV-ZEBOV (Ebola) vaccine candidate was originally developed by the Public Health Agency of Canada (PHAC), and was subsequently licensed to a subsidiary of NewLink Genetics. In late 2014, Merck licensed the vaccine from NewLink Genetics to apply Merck’s vaccine expertise to help accelerate the development of this promising candidate. Merck is now responsible for research, development and manufacturing of the rVSV-ZEBOV vaccine.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up